

IN THE CLAIMS

Please amend the claims as follows:

Sub.D1 > 1. (Twice Amended) A method for preventing
constrictive vascular remodeling comprising a controlled
delivery, by release from an intraluminal medical device, of a
compound having anti-proliferative and anti-inflammatory
properties in therapeutic dosage amounts, the compound
substantially reducing in-lesion lumen loss both proximate and
distal to the intraluminal medical device.

Sub.D1 > 8. (Twice Amended) A drug delivery device for
treating constrictive vascular remodeling comprising:

an intraluminal medical device; and

a therapeutic dosage of an agent having anti-
proliferative and anti-inflammatory properties releasably
affixed to the intraluminal medical device for treatment of
constrictive vascular remodeling, the agent substantially
reducing in-lesion lumen loss both proximal and distal to the
intraluminal medical device.

REMARKS

In response to the Final Office Action mailed February 11,
2003, Applicants propose to amend their application and request
reconsideration in view of the proposed amendments and the
following remarks in this Reply/Amendment. Claims 1 and 8 were